Investor Relations

Viracta is a precision oncology company targeting virus-associated malignancies. The Company's proprietary investigational drug, nanatinostat, is currently being evaluated in combination with the antiviral agent valganciclovir as an oral combination therapy in a Phase 2 clinical trial for EBV-positive lymphomas. Viracta is pursuing application of this inducible synthetic lethality approach in other EBV-associated malignancies, such as nasopharyngeal carcinoma, gastric carcinoma, and other virus-related cancers.

August Corporate Presentation

Stock Info
NASDAQVIRX
Recent News
Oct 6, 2021

Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced the initiation of a multinational Phase 1b/2 trial in patients with...

Sep 7, 2021

Viracta Therapeutics, Inc. (NASDAQ: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that company management will present and be available for virtual...

Aug 23, 2021

Viracta Therapeutics, Inc. (NASDAQ: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that it has reacquired the exclusive rights to develop and...

View All

Events
Thursday, September 30, 2021
8:40am EDT
Tuesday, September 21, 2021
4:35pm EDT
Monday, September 13, 2021
7:00am EDT

View All

Investor Contact

Dan Chevallard
Chief Operating Officer and Chief Financial Officer
Viracta Therapeutics, Inc.
(o) (858) 771-4193